These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25524176)

  • 1. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy.
    Chen TT; Chiu CF; Yang TY; Lin CC; Sargeant AM; Yeh SP; Liao YM; Bai LY
    Leuk Res; 2015 Feb; 39(2):151-6. PubMed ID: 25524176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
    Salah-Eldin MA; Ebrahim MA; El-Sadda W
    Ann Hematol; 2014 Nov; 93(11):1903-11. PubMed ID: 24951125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
    Nishikawa H; Tsudo M; Osaki Y
    Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
    Ennishi D; Maeda Y; Niitsu N; Kojima M; Izutsu K; Takizawa J; Kusumoto S; Okamoto M; Yokoyama M; Takamatsu Y; Sunami K; Miyata A; Murayama K; Sakai A; Matsumoto M; Shinagawa K; Takaki A; Matsuo K; Kinoshita T; Tanimoto M
    Blood; 2010 Dec; 116(24):5119-25. PubMed ID: 20823454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
    Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O;
    J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Dlouhy I; Torrente MÁ; Lens S; Rovira J; Magnano L; Giné E; Delgado J; Balagué O; Martínez A; Campo E; Forns X; Sánchez-Tapias JM; López-Guillermo A
    Ann Hematol; 2017 Mar; 96(3):405-410. PubMed ID: 28035434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
    Nooka A; Shenoy PJ; Sinha R; Lonial S; Flowers CR
    Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):379-84. PubMed ID: 21729690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
    Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
    Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
    Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
    Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
    Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
    Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index.
    Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC
    Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
    Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
    Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients with transformed lymphoma in the rituximab era.
    Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
    Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.